News 2017-10-27
2018 CPhI WW — A Window to the Global Pharmaceutical Supply Chain
Continuing a long and respected tradition, CPhI WW’s Annual Meeting was held during October 24-26, 2017 at the Messe Frankfurt Exhibition Center, Germany. As the world’s leading exhibition and meeting place in the area of pharmaceutical ingredients, the event brought global pharmaceutical companies, manufacturers and professionals together in a joint quest for continued supply chain innovation, reliability and quality.
As a top-tier external manufacturing partner and strategic supplier of custom drug intermediates and APIs to many of the world’s leading pharmaceutical companies, a high-powered Porton delegation led by Chairman & CEO Mr. Oliver Ju attended this marquee 3-day event. Porton’s executives had more than 70 meetings with customers at over 50 global pharmaceutical companies including 12 of the Top 20 Big Pharma, such as Janssen, Gilead, Pfizer, Novartis and etc. We also met with dozens of specialty pharmaceutical and biotechnology companies across the US and Europe in reference to ongoing and projected R&D and external manufacturing collaborations.
Also continuing a recently set precedent, Porton hosted a Wine + Tapas Social at our booth for customers, industry stakeholders and media on Wednesday, October 25, 2017. Featuring music, French wines and small plate appetizers, Porton’s executives cultivated valued relationships with many customers and prospective partners during this informal late afternoon event – setting the stage for additional future discussions.
Others
More
News 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.
